257 related articles for article (PubMed ID: 33326644)
41. Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma.
Chong CC; Cheung ST; Cheung YS; Chan AW; Chan SL; Yu SC; Lai PB
Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):524-530. PubMed ID: 30413348
[TBL] [Abstract][Full Text] [Related]
42. Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas.
Cheung TT; Poon RT; Jenkins CR; Chu FS; Chok KS; Chan AC; Tsang SH; Dai WC; Yau TC; Chan SC; Fan ST; Lo CM
Liver Int; 2014 Jul; 34(6):e136-43. PubMed ID: 24451026
[TBL] [Abstract][Full Text] [Related]
43. Large hepatocellular carcinomas: treatment with transarterial chemoembolization alone or in combination with percutaneous cryoablation.
Cui W; Fan W; Huang K; Wang Y; Lu M; Yao W; Li J
Int J Hyperthermia; 2018; 35(1):239-245. PubMed ID: 30200796
[TBL] [Abstract][Full Text] [Related]
44. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone.
Smolock AR; Cristescu MM; Hinshaw A; Woo KM; Wells SA; Ziemlewicz TJ; Lubner MG; Dalvie PS; Louis Hinshaw J; Brace CL; Ozkan OS; Lee FT; Laeseke P
Abdom Radiol (NY); 2018 Sep; 43(9):2497-2504. PubMed ID: 29450606
[TBL] [Abstract][Full Text] [Related]
45. Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.
Takamori S; Takada K; Tagawa T; Toyokawa G; Hirai F; Yamashita N; Okamoto T; Oki E; Yoshizumi T; Oda Y; Maehara Y
Surg Oncol; 2018 Dec; 27(4):637-641. PubMed ID: 30449485
[TBL] [Abstract][Full Text] [Related]
46. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
[TBL] [Abstract][Full Text] [Related]
47. Drug-Eluting Microsphere Versus Cisplatin-Based Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: Propensity Score-Matched Analysis.
Chu HH; Gwon DI; Kim JH; Ko GY; Shin JH; Yoon HK
AJR Am J Roentgenol; 2020 Sep; 215(3):745-752. PubMed ID: 32569514
[No Abstract] [Full Text] [Related]
48. Prognostic Significance of ¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study.
Lee JW; Oh JK; Chung YA; Na SJ; Hyun SH; Hong IK; Eo JS; Song BI; Kim TS; Kim DY; Kim SU; Moon DH; Lee JD; Yun M
J Nucl Med; 2016 Apr; 57(4):509-16. PubMed ID: 26742711
[TBL] [Abstract][Full Text] [Related]
49. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
Schneider S; Kadletz L; Wiebringhaus R; Kenner L; Selzer E; Füreder T; Rajky O; Berghoff AS; Preusser M; Heiduschka G
Histopathology; 2018 Oct; 73(4):573-584. PubMed ID: 29742291
[TBL] [Abstract][Full Text] [Related]
50. Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia.
Rahman FA; Naidu J; Ngiu CS; Yaakob Y; Mohamed Z; Othman H; Jarmin R; Elias MH; Hamid NA; Mokhtar NM; Ali RR
Asian Pac J Cancer Prev; 2016; 17(8):4037-41. PubMed ID: 27644658
[TBL] [Abstract][Full Text] [Related]
51. Programmed death receptor Ligand 1 expression in eyelid sebaceous carcinoma: a consecutive case series of 41 patients.
Xu S; Yu H; Fu G; Fan X; Jia R
Acta Ophthalmol; 2019 May; 97(3):e390-e396. PubMed ID: 29862664
[TBL] [Abstract][Full Text] [Related]
52. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?
Otto G; Schuchmann M; Hoppe-Lotichius M; Heise M; Weinmann A; Hansen T; Pitton MP
J Hepatol; 2013 Aug; 59(2):279-84. PubMed ID: 23587474
[TBL] [Abstract][Full Text] [Related]
53. Aligning digital CD8
Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
[TBL] [Abstract][Full Text] [Related]
54. Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature.
Fouad M; Abdel-Rahman O
Arab J Gastroenterol; 2015 Jun; 16(2):40-5. PubMed ID: 25910573
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India.
Vallonthaiel AG; Malik PS; Singh V; Kumar V; Kumar S; Sharma MC; Mathur S; Arava S; Guleria R; Jain D
Ann Diagn Pathol; 2017 Dec; 31():56-61. PubMed ID: 29146060
[TBL] [Abstract][Full Text] [Related]
56. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma.
Xu B; Jungbluth AA; Frosina D; Alzumaili B; Aleynick N; Slodkowska E; Higgins K; Ho A; Morris L; Ghossein R; Katabi N
Histopathology; 2019 Nov; 75(5):672-682. PubMed ID: 31237963
[TBL] [Abstract][Full Text] [Related]
57. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman O; Elsayed Z
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
[TBL] [Abstract][Full Text] [Related]
58. Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
PLoS One; 2021; 16(9):e0257860. PubMed ID: 34559865
[TBL] [Abstract][Full Text] [Related]
59. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
Zong L; Sun Z; Mo S; Lu Z; Yu S; Xiang Y; Chen J
Gynecol Oncol; 2021 Sep; 162(3):631-637. PubMed ID: 34272092
[TBL] [Abstract][Full Text] [Related]
60. Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial.
Yang M; Fang Z; Yan Z; Luo J; Liu L; Zhang W; Wu L; Ma J; Yang Q; Liu Q
J Cancer Res Clin Oncol; 2014 Feb; 140(2):211-9. PubMed ID: 24374800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
